OAS1, OAS2, and OAS3 Contribute to Epidermal Keratinocyte Proliferation by Regulating Cell Cycle and Augment Type I Interferon-Induced JAK1-STAT1 Phosphorylation in Psoriasis
Yan-Zhou Huang,Yu-Xin Zheng,Yuan Zhou,Fan Xu,Ying-Zhe Cui,Xue-Yan Chen,Zhao-Yuan Wang,Bing-Xi Yan,Min Zheng,Xiao-Yong Man
DOI: https://doi.org/10.1016/j.jid.2022.02.018
IF: 7.59
2022-03-01
Journal of Investigative Dermatology
Abstract:Psoriasis is a systemic immune-mediated inflammatory disease characterized by hyperproliferation and abnormal differentiation of epidermal keratinocytes. Recent studies have identified IL-17 and IL-23 as key drivers of psoriasis pathogenesis, but the underlying molecular mechanisms remain unclear. The 2'-5'-oligoadenylate synthetases, namely, OAS1, OAS2, OAS3, and OASL, are a family of interferon-induced enzymes with multiple antiviral activities, but their role in psoriasis is unknown. Here, we identified overexpression of OAS1, OAS2, and OAS3 in human lesional psoriatic skin and serum and found that their expression was downregulated by biologics. Moreover, OASs were highly expressed in epidermal keratinocytes, epidermal dendritic cells, epidermal CD3 T cells, dermal antigen-presenting cells, and dermal T cells from the psoriatic epidermis and dermis, as determined by flow cytometry. Additionally, OASs were upregulated by poly(I:C), poly(dA:dT), and type I IFNs but downregulated by JAK inhibitors in normal human epidermal keratinocytes. Furthermore, silencing of OASs inhibited the phosphorylation of JAK1 and STAT1. Knockdown of OASs suppressed keratinocyte proliferation by inhibiting cell cycle progression. Thus, OASs may be therapeutic biomarkers in psoriasis.
dermatology